EBITDA: Income before interest, taxes, depreciation and amortization.
Alzamend Neuro, Inc. (ALZN) had EBITDA of $-2.17M for the most recently reported fiscal quarter, ending 2026-01-31.
| Income Statement Financials | |
-- |
|
$-2.20M |
|
-- |
|
-- |
|
$2.20M |
|
$-2.20M |
|
$-0.00M |
|
$-2.20M |
|
$-2.20M |
|
$-2.20M |
|
$-2.20M |
|
$-2.20M |
|
$-2.20M |
|
$-2.20M |
|
|
EBITDA |
$-2.17M |
3.80M |
|
3.80M |
|
$-0.58 |
|
$-0.58 |
|
| Balance Sheet Financials | |
$3.70M |
|
$0.34M |
|
$0.34M |
|
$4.04M |
|
$1.86M |
|
-- |
|
-- |
|
$1.86M |
|
$2.18M |
|
$2.18M |
|
$2.18M |
|
3.81M |
|
| Cash Flow Statement Financials | |
$-5.27M |
|
-- |
|
$4.04M |
|
$3.95M |
|
$2.71M |
|
$-1.24M |
|
$0.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-100.66% |
|
-100.66% |
|
-54.41% |
|
-100.66% |
|
$0.57 |
|
$-1.39 |
|
$-1.39 |
|